Ibrahem Salma Mahfouz, Ahmed Eman Hasan, Shafik Engy Adel, Hetta Helal F, Bakry Rania Mohamed
Department of Clinical Pathology, South Egypt Cancer Institute, Assiut University, Assiut, Egypt.
Division of Microbiology, Immunology and Biotechnology, Department of Natural Products and Alternative Medicine, Faculty of Pharmacy, University of Tabuk, 71491, Tabuk, Saudi Arabia.
Mol Biol Rep. 2025 Jan 7;52(1):105. doi: 10.1007/s11033-024-10113-7.
Acute myeloid leukemia (AML) is a remarkably complex malignancy; with considerable genetic, epigenetic, and phenotypic heterogenicity. Circ-RNAs are a novel class of non-coding RNA. They may influence leukemia development and offer exciting possibilities for targeted AML diagnosis and therapy. This study aimed to detect circ_0002232 and circ-VIM expression levels in AML patients and their relation to the clinicopathological characteristics and disease outcome to assess the prognostic potential of both circ-RNAs and achieve a new target therapy for the disease.
Circ_0002232 and circ-VIM gene expressions were measured in 60 AML patients and 30 controls using qRT-PCR.
Circ_0002232 was significantly downregulated in our patients compared to controls (P value < 0.001). On the other hand, circ-VIM was notably upregulated in our patients (P value = 0.005). Using ROC curve, circ_0002232 and circ-VIM biomarkers could distinguish AML patients from controls with AUC 0.847, 0.683 and P value < 0.0001, = 0.004 respectively. Patients with downregulated circ_0002232 were significantly younger than upregulated patients (p value = 0.003). In addition, downregulated circ_0002232 was significantly associated with decreased hemoglobin level and increased overall survival (OS). Regarding high circ-VIM expression in AML patients, it was significantly correlated with lacking complete remission and leukocytosis.
Circ_0002232 and circ-VIM could be valuable diagnostic biomarkers to differentiate AML patients from healthy controls in clinical use. Circ-VIM expression may influence AML prognosis. Further research is needed to validate the clinical utility of circ_0002232 as a prognostic marker for OS in AML patients.
急性髓系白血病（AML）是一种极其复杂的恶性肿瘤，具有显著的遗传、表观遗传和表型异质性。环状RNA是一类新型的非编码RNA。它们可能影响白血病的发展，并为AML的靶向诊断和治疗提供令人兴奋的可能性。本研究旨在检测AML患者中circ_0002232和circ-VIM的表达水平及其与临床病理特征和疾病预后的关系，以评估这两种环状RNA的预后潜力，并为该疾病实现新的靶向治疗。
采用qRT-PCR检测60例AML患者和30例对照中circ_0002232和circ-VIM基因的表达。
与对照组相比，我们的患者中circ_0002232显著下调（P值<0.001）。另一方面，我们的患者中circ-VIM显著上调（P值=0.005）。使用ROC曲线，circ_0002232和circ-VIM生物标志物可以区分AML患者和对照组，AUC分别为0.847、0.683，P值分别<0.0001、=0.004。circ_0002232下调的患者比上调的患者明显年轻（p值=0.003）。此外，circ_0002232下调与血红蛋白水平降低和总生存期（OS）延长显著相关。关于AML患者中circ-VIM的高表达，它与未完全缓解和白细胞增多显著相关。
Circ_0002232和circ-VIM可能是临床应用中区分AML患者和健康对照的有价值的诊断生物标志物。Circ-VIM表达可能影响AML预后。需要进一步研究来验证circ_0002232作为AML患者OS预后标志物的临床实用性。
